With multiple, complex chromatographic purification, buffer exchange, and viral inactivation steps, downstream processing of monoclonal antibodies (mAbs) remains the major bottleneck in ...

Optimizing the downstream process for adeno-associated virus (AAV) production with consistent quality depends on the ability to characterize critical quality attributes affecting the final product’s ...

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Upstream and Downstream Manufacturing in the Biopharmaceutical Industry (June 11, 2026)" training has been added to ResearchAndMarkets.com's offering.

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Bispecific antibodies represent a rapidly expanding class of biotherapeutics, presenting distinct innovation trends across ...

Drug development and manufacturing have undergone a seismic shift in the last two decades, 1 from blockbuster small molecules to highly personalized biologics 2 and cell and gene therapies. Because ...

The current discussion of downstream bottlenecks arises from the ease with which up-stream activities generate protein and the desire for downstream operations to match upstream productivity. “In ...

Between 2026 and 2028, the U.S. downstream solar community must focus its attention on domestic solar cell production to ...

The U.S. Preparative and Process Chromatography Market is projected to reach USD 7.28 Billion by 2035, while Europe is ...